摘要
2017年11月,美国、欧盟和日本共批准38个新药,包括新分子实体、新有效成分、新生物制品、新增适应证及新剂型药物。对全球首次获得批准的新分子实体、新有效成分、新生物制品进行分析,重点介绍这些药物的临床研究结果和研发历史进程。
In November 2017, US Food and Drug Administration (FDA), European Commission, and Japanese Ministry of Health, Labour and Welfare (MHLW) had totally approved 38 new drugs, including new molecular entities, new active ingredient, new biologics and new line extensions (new indications and new formulations), in this article, new molecular entities, new active ingredients and new biologics receiving their first global approval were analyzed with emphasis on the outcomes of clinical trials and development histories.
出处
《药学进展》
CAS
2017年第12期957-960,I0001,共5页
Progress in Pharmaceutical Sciences
关键词
新药批准
临床试验
新分子实体
新生物制品
drug approval
clinical trial
new molecular entity: new biologics